Hyderabad made a big investment in the life science sector on Wednesday. US-based Stemcures is all set to set up a manufacturing lab in the Telangana capital with a focus on stem cell therapy. The firm aims to set up the largest stem cell manufacturing plant in India. The facility will be set up with an investment potential of around $54 million and employment potential for around 150 people in phases.
Citing a statement from the minister’s office in Hyderabad, IANS reported that the plant will focus on the latest technology and expertise that the US has to offer to manufacture high-quality, affordable stem cell products.
Medical Leap for Make in India
Atluri, who traces his roots to Hyderabad, said it was a seamless experience considering that his company already has an R&D facility in Hyderabad. The report mentions that Stemcure is concluding the research and development of the stem cell line at Aspire BioNest at the University of Hyderabad.
“We are now looking forward to expanding with a manufacturing plant,” Dr. Atluri said.
Hyderabad currently serves over 1,000 life science companies including top 10 pharma companies. Four out of the top 10 global innovators in the region now have a direct presence in the city through their dedicated centres.
accessible stem cell therapy
Stem cell therapy is a treatment that uses a patient’s own stem cells to treat a condition. Stem cells can become any cell in the body, so injecting them into an injured area can repair tissue, reduce inflammation, and promote healing. This is through a non-surgical and minimally invasive treatment plan.
The investment was announced following a meeting of Dr. Sairam Atluri, Founder of Stemcures, with KT Rama Rao, IT and Industries Minister of Telangana, in Boston.
KTR called stem cell therapy a promising new treatment for a variety of conditions. “I am confident that StemCures will continue to provide high-quality care to patients in India. I look forward to working with the clinic to make stem cell therapy more accessible to patients in India,” he added.